ERBB2 and breast cancer: A published report describes the case of a 63-year-old woman with recurrent ER+/HER2+ BC and a NCOA4-RET rearrangement that achieved a clinical and radiological response to the combination of cabozantinib, trastuzumab and exemestane (45).